{"id":27955,"date":"2025-11-07T15:56:56","date_gmt":"2025-11-07T08:56:56","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=27955"},"modified":"2025-11-07T15:56:56","modified_gmt":"2025-11-07T08:56:56","slug":"metoprolol-succinate","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/metoprolol-succinate\/","title":{"rendered":"Metoprolol Succinate"},"content":{"rendered":"

Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n

(Ph. Eur. monograph 1448)<\/p>\n

\"Metoprolol<\/p>\n

C34<\/sub>H56<\/sub>N2<\/sub>O10<\/sub> 653 98418-47-4<\/p>\n

Action and use<\/strong><\/p>\n

Beta-adrenoceptor antagonist.<\/p>\n

Ph Eur<\/p>\n

DEFINITION<\/h2>\n

Bis[(2RS)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]propan-2-ol] butanedioate.<\/p>\n

Content<\/strong><\/p>\n

99.0 per cent to 101.0 per cent (dried substance).<\/p>\n

CHARACTERS<\/h2>\n

Appearance<\/h3>\n

White or almost white, crystalline powder.<\/p>\n

Solubility<\/h3>\n

Freely soluble in water, soluble in methanol, slightly soluble in ethanol (96 per cent), very slightly soluble in ethyl acetate.<\/p>\n

IDENTIFICATION<\/h3>\n

Infrared absorption spectrophotometry (2.2.24).<\/p>\n

Comparison Ph. Eur. reference spectrum of metoprolol succinate.<\/p>\n

TESTS<\/h3>\n

Solution S<\/h3>\n

Dissolve 0.500 g in carbon dioxide-free water R and dilute to 25.0 mL with the same solvent.<\/p>\n

Appearance of solution<\/h3>\n

Solution S is not more opalescent than reference suspension II (2.2.1) and is colourless (2.2.2, Method II).<\/p>\n

pH (2.2.3)<\/h2>\n

7.0 to 7.6 for solution S.<\/p>\n

Impurities M, N, O<\/h3>\n

Thin-layer chromatography (2.2.27).<\/p>\n

Test solution Dissolve 0.50 g of the substance to be examined in methanol R and dilute to 10 mL with the same solvent.<\/p>\n

Reference solution Dilute 1 mL of the test solution to 50 mL with methanol R. Dilute 5 mL of this solution to 50 mL with methanol R.<\/p>\n

Plate TLC silica gel plate R.<\/p>\n

Mobile phase Place 2 beakers, each containing 30 volumes of concentrated ammonia R, at the bottom of a chromatographic tank containing a mixture of 20 volumes of methanol R and 80 volumes of ethyl acetate R.<\/p>\n

Application 10 \u03bcL.<\/p>\n

Development Over 2\/3 of the plate in a tank saturated for at least 1 h.<\/p>\n

Drying In air for at least 3 h.<\/p>\n

Detection Expose the plate to iodine vapour for at least 15 h.<\/p>\n

Limits:<\/p>\n

– any impurity: any spot, apart from the principal spot, is not more intense than the spot in the chromatogram obtained with the reference solution (0.2 per cent);<\/p>\n

– disregard any spot on the line of application.<\/p>\n

Related substances<\/h3>\n

Liquid chromatography (2.2.29).<\/p>\n

Test solution Dissolve 20.0 mg of the substance to be examined in the mobile phase and dilute to 10.0 mL with the mobile phase.<\/p>\n

Reference solution (a) Dissolve 1.5 mg of metoprolol impurity A CRS and 2.5 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase.<\/p>\n

Reference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.<\/p>\n

Column:<\/p>\n

– size: l = 0.15 m, \u00d8 = 3.9 mm;<\/p>\n

– stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 \u03bcm).<\/p>\n

Mobile phase Dissolve 3.9 g of ammonium acetate R in 810 mL of water R, add 2.0 mL of triethylamine R, 3.0 mL of phosphoric acid R, 10.0 mL of glacial acetic acid R and 146 mL of acetonitrile R and mix.<\/p>\n

Flow rate 1 mL\/min.<\/p>\n

Detection Spectrophotometer at 280 nm.<\/p>\n

Injection 20 \u03bcL.<\/p>\n

Run time 3 times the retention time of metoprolol.<\/p>\n

Relative retention With reference to metoprolol (retention time = about 7 min): impurity C = about 0.4;<\/p>\n

impurity A = about 0.8.<\/p>\n

System suitability Reference solution (a):<\/p>\n

– resolution: minimum 6.0 between the peaks due to impurity A and metoprolol.<\/p>\n

Limits:<\/p>\n

– correction factor: for the calculation of content, multiply the peak area of impurity C by 0.1;<\/p>\n

– impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.15 per cent);<\/p>\n

– unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);<\/p>\n

– total: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);<\/p>\n

– disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent); disregard any peak due to succinic acid.<\/p>\n

Loss on drying (2.2.32)<\/h3>\n

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C.<\/p>\n

Sulfated ash (2.4.14)<\/h3>\n

Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n

ASSAY<\/h2>\n

Dissolve 0.250 g in 40 mL of anhydrous acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).<\/p>\n

1 mL of 0.1 M perchloric acid is equivalent to 32.64 mg of C34H56N2O10.<\/p>\n

STORAGE<\/h2>\n

Protected from light.<\/p>\n

IMPURITIES<\/h2>\n

Specified impurities C, M, N, O.<\/p>\n

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, D, E, F, G, H, J.<\/p>\n

\"Metoprolol<\/p>\n

A. (2RS)-1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol,<\/p>\n

\"Metoprolol<\/p>\n

B. 4-(2-methoxyethyl)phenol,<\/p>\n

\"Metoprolol<\/p>\n

C. 4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzaldehyde,<\/p>\n

\"Metoprolol<\/p>\n

D. (2RS)-3-[4-(2-methoxyethyl)phenoxy]propane-1,2-diol,<\/p>\n

\"Metoprolol<\/p>\n

E. (2RS)-1-[2-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]propan-2-ol,<\/p>\n

\"Metoprolol<\/p>\n

F. (2RS)-1-[(1-methylethyl)amino]-3-phenoxypropan-2-ol,<\/p>\n

\"Metoprolol<\/p>\n

G. 2-(4-hydroxyphenyl)ethanol,<\/p>\n

\"Metoprolol<\/p>\n

H. (2RS)-1-[4-(2-hydroxyethyl)phenoxy]-3-[(1-methylethyl)amino]propan-2-ol,<\/p>\n

\"Metoprolol<\/p>\n

J. mixture of the 4 stereoisomers of 1-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-3-[4-(2-<\/p>\n

\"Metoprolol<\/p>\n

M. 1,3-bis[(1-methylethyl)amino]propan-2-ol,<\/p>\n

\"Metoprolol<\/p>\n

N. (2RS)-3-[(1-methylethyl)amino]propane-1,2-diol,<\/p>\n

\"Metoprolol<\/p>\n

O. mixture of the 3 stereoisomers of 1,1\u2032-[(1-methylethyl)imino]bis[3-[4-(2-methoxyethyl)phenoxy]propan-2-ol].<\/p>\n

Ph Eur<\/p>\n","protected":false},"excerpt":{"rendered":"

Edition: BP 2025 (Ph. Eur. 11.6 update) (Ph. Eur. monograph 1448) C34H56N2O10 653 98418-47-4 Action and use Beta-adrenoceptor antagonist. Ph Eur DEFINITION Bis[(2RS)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]propan-2-ol] butanedioate. Content 99.0 per cent to 101.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Freely soluble in water, soluble in methanol, slightly soluble in ethanol (96…<\/p>\n","protected":false},"author":5,"featured_media":27980,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-27955","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/27955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=27955"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/27955\/revisions"}],"predecessor-version":[{"id":27987,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/27955\/revisions\/27987"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/27980"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=27955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=27955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=27955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}